Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter P Toth

Showing results (251-260 of 425) with videos related to

Pageof 43
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|September 14, 2023
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart AssociationLarry B Goldstein, Peter P Toth, Jennifer L Dearborn-Tomazos, et al.
Journal of Diabetes and Its Complications|May 31, 2016
Statin therapy and inflammation in patients with diabetes treated with high dose aspirinRahul Chaudhary, Kevin P Bliden, Jalaj Garg, et al.
Frontiers in Cardiovascular Medicine|March 31, 2025
Cross-Sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethylPeter P Toth, John R Nelson, Handrean Soran, et al.
Clinical Therapeutics|February 29, 2016
Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed DyslipidemiaP Elliott Miller, Seth S Martin, Parag H Joshi, et al.
Journal of Clinical Lipidology|March 6, 2012
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reductionPeter P Toth, Christie M Ballantyne, Michael H Davidson, et al.
The American Journal of Cardiology|March 12, 2015
Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapyChristopher J Franzese, Kevin P Bliden, Martin G Gesheff, et al.
Journal of Interventional Cardiology|January 30, 2016
Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent RestenosisKevin P Bliden, Udaya S Tantry, Martin G Gesheff, et al.
Frontiers in Pharmacology|January 19, 2016
Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective StudyPeter P Toth, Angelo M Patti, Dragana Nikolic, et al.
The American Journal of Cardiology|December 10, 2017
Effect of Evolocumab on Lipoprotein ParticlesPeter P Toth, Naveed Sattar, Dirk J Blom, et al.
Journal of the American Heart Association|April 24, 2014
Narrowing sex differences in lipoprotein cholesterol subclasses following mid-life: the very large database of lipids (VLDL-10B)Kristopher J Swiger, Seth S Martin, Michael J Blaha, et al.
Pageof 43

Showing results (251-260 of 425) with videos related to

Sort By:
Pageof 43
Arteriosclerosis, Thrombosis, and Vascular Biology|September 14, 2023
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart AssociationLarry B Goldstein, Peter P Toth, Jennifer L Dearborn-Tomazos, et al.
Journal of Diabetes and Its Complications|May 31, 2016
Statin therapy and inflammation in patients with diabetes treated with high dose aspirinRahul Chaudhary, Kevin P Bliden, Jalaj Garg, et al.
Frontiers in Cardiovascular Medicine|March 31, 2025
Cross-Sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethylPeter P Toth, John R Nelson, Handrean Soran, et al.
Clinical Therapeutics|February 29, 2016
Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed DyslipidemiaP Elliott Miller, Seth S Martin, Parag H Joshi, et al.
Journal of Clinical Lipidology|March 6, 2012
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reductionPeter P Toth, Christie M Ballantyne, Michael H Davidson, et al.
The American Journal of Cardiology|March 12, 2015
Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapyChristopher J Franzese, Kevin P Bliden, Martin G Gesheff, et al.
Journal of Interventional Cardiology|January 30, 2016
Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent RestenosisKevin P Bliden, Udaya S Tantry, Martin G Gesheff, et al.
Frontiers in Pharmacology|January 19, 2016
Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective StudyPeter P Toth, Angelo M Patti, Dragana Nikolic, et al.
The American Journal of Cardiology|December 10, 2017
Effect of Evolocumab on Lipoprotein ParticlesPeter P Toth, Naveed Sattar, Dirk J Blom, et al.
Journal of the American Heart Association|April 24, 2014
Narrowing sex differences in lipoprotein cholesterol subclasses following mid-life: the very large database of lipids (VLDL-10B)Kristopher J Swiger, Seth S Martin, Michael J Blaha, et al.
Pageof 43